EP1467742A1 - Verwendung von alkylphosphocholinen in der pr ventivbehandlung von protozoenerkrankungen - Google Patents

Verwendung von alkylphosphocholinen in der pr ventivbehandlung von protozoenerkrankungen

Info

Publication number
EP1467742A1
EP1467742A1 EP03731619A EP03731619A EP1467742A1 EP 1467742 A1 EP1467742 A1 EP 1467742A1 EP 03731619 A EP03731619 A EP 03731619A EP 03731619 A EP03731619 A EP 03731619A EP 1467742 A1 EP1467742 A1 EP 1467742A1
Authority
EP
European Patent Office
Prior art keywords
use according
active ingredient
hexadecylphosphocholine
leishmaniasis
miltefosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03731619A
Other languages
German (de)
English (en)
French (fr)
Inventor
Jürgen Engel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of EP1467742A1 publication Critical patent/EP1467742A1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to alkylphosphocholines, in particular hexadecylphosphocholine (Miltefosine) or octadecyl (1,1-dimethylpiperidino-4-yl) -phosphate (perifosine, D-21266), pharmaceutical compositions for oral administration in the preventive treatment of protozoal diseases , in particular leishmaniasis, and a dosage regimen for the oral administration of said pharmaceutical composition in the preventive treatment of protozoal diseases, in particular leishmaniasis, and a combination comprising said pharmaceutical composition, an antiemetic and / or an antidiarrheal.
  • pharmaceutical compositions for oral administration in the preventive treatment of protozoal diseases in particular leishmaniasis
  • a dosage regimen for the oral administration of said pharmaceutical composition in the preventive treatment of protozoal diseases in particular leishmaniasis
  • a combination comprising said pharmaceutical composition, an antiemetic and / or an antidiarrheal.
  • Leishmaniasis is a term for various tropical diseases, which are caused by flagellates of the genus Leishmania and transmitted by various blood-sucking insects.
  • the manifestations of leishmaniasis may be visceral (Kala-Azar), mucocutaneous (American leishmaniasis) or cutaneous (Aleppo's bump or diffuse cutaneous leishmaniasis).
  • the incubation period is weeks to months. Especially in the case of Kala-Azar and American leishmaniasis a very high mortality rate is observed in untreated cases.
  • Pentavalent antimony compounds eg sodium stibogluconate
  • aromatic diamidines had to be administered by parenteral injection, which not only led to serious side effects due to their high toxicity, but also included a risk of infection.
  • alkylphosphocholines in particular hexadecylphosphocholine (miltefosine)
  • hexadecylphosphocholine vandecylphosphocholine
  • T. Jha et al., Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis N. Engl. J. Med. (1999), 341 (24), 1795-1800 report a study of 120 patients, where 50 to 150 mg of miltefosine per day was used for several weeks.
  • Miltefosine is difficult to handle, although it is available in dry form as crystalline platelets with a defined melting point in excess of 200 ° C since it is very hygroscopic.
  • the uptake of water molecules can lead to an increase in weight of up to 30% by weight, a lowering of the melting point and a caking and clumping of the crystals.
  • the processability of the hydrous miltefosine is insufficient for further processing into solid pharmaceutical compositions such as tablets, capsules or sachets.
  • the fluidity of hydrous miltefosine is insufficient. Satisfactory flowability, however, is one of the indispensable prerequisites for the production of pharmaceutical compositions on an industrial scale.
  • anhydrous miltefosine exhibits a considerable tendency to electrostatic charge, especially when stirred in a dry state.
  • the fluidity of electrostatically charged miltefosine is insufficient for further processing into solid pharmaceutical compositions.
  • electrostatic charges are always associated with significant safety concerns because of the associated risks of both explosions and damage to sensitive electronic parts.
  • WO 99/37289 it is possible, by simple physical mixing of alkylphosphocholines, in particular miltefosinv, to obtain a flow agent and / or lubricant and at least one filler, a solid pharmaceutical mixture having a fluidity which is sufficient for further processing, for example into capsules, Tablets or sachets.
  • the solid pharmaceutical composition can be filled into capsules, preferably hard gelatine capsules, or pressed into tablets or effervescent tablets or, as a drinking mixture or effervescent mixture, filled into sachets.
  • the content of miltefosine per unit dose is in the range of 10 to 800 mg, preferably in the range of 10 to 500 mg and more preferably in the range of 50 to 250 mg. The most preferred content is in the range of 50 to 150 mg.
  • miltefosine is described in detail in the examples of hexadecylphosphocholine in the German patent application DE-A-4132344. Further methods for producing and purifying miltefosine are described, for example, in German patent applications DE-A 2752125, DE-A 3641379, DE-A 3641491, DE-A 4013632 and DE-A 3641377.
  • alkylphosphocholines in particular
  • Hexadecylphosphocholine (Miltefosine) or octadecyl (1,1-dimethylpiperidinio-4-yl) -phosphate (Perifosin, D-21266) are suitable for a preventive treatment of protozoal diseases, in particular leishmaniasis.
  • Alkylphosphocholines in particular hexadecylphosphocholine or octadecyl (1,1-dimethylpiperidinio-4-yl) phosphate for the prevention of protozoal diseases, in particular leishmaniasis, are neither described nor suggested in the prior art reports.
  • a dosage regimen for the preventive treatment of leishmaniasis in humans by oral administration of the pharmaceutical composition is provided.
  • the following dosage regimen is useful for the preventive treatment of leishmaniasis in humans by oral administration:
  • Total daily dose 10-250 mg of miltefosine active, preferably 20-150 mg, especially 30-100 mg; daily single or multiple dose: a total daily dose of 10-50 mg of active ingredient is preferably administered as a single daily dose; a dose of 50-250 mg active ingredient, preferably 50-150 mg active ingredient, is administered orally daily as a multiple daily dose, preferably as two doses per day (total daily dose 100 mg active ingredient) or as three doses per day (total daily dose 150 mg active ingredient).
  • a daily dose divided into 4-5 doses is generally considered to be the upper limit. For preventive purposes, however, it is also possible to administer the remedy differently than divided into 1-5 doses per day.
  • Prophylaxis is also possible with an initial dose followed by maintenance doses using as initial dose e.g. 100 mg or more of active ingredient, followed by maintenance doses of e.g. B. 30 mg of active ingredient.
  • Prophylactic duration of use 2 weeks to 6 months, preferably over the duration of the risk of infection.
  • a dosage regimen for the preventive treatment of leishmaniasis in non-human mammals by oral administration of the pharmaceutical composition of the invention is provided.
  • the dosing regimen enables the preventive treatment of all types of leishmaniasis, in particular leishmaniasis major and leishmaniase infantum.
  • the total daily dose in the case of prophylactic treatment in the case of oral administration is in the range of 0.5-15 mg of miltefosine or perifosin active ingredient per kg body weight of the animal (mg active substance / kg).
  • prophylaxis is initiated with a total initial dose (loading dose) in the range of 3-15, preferably 5-10 mg / kg and then with a total daily dose (maintenance doses) in the range of 1-10, preferably 3-5 mg of drug / kg continued.
  • the preventive application period is in the range from 2 weeks to 6 months, preferably over the duration of the risk of infection.
  • the pharmaceutical composition according to the invention is administered in combination with an antiemetic and / or an antidiarrhoeal agent.
  • Administration may be simultaneous or sequential.
  • Antiemetic and antidiarrhoeal can be administered independently.
  • the antiemetic and / or antidiarrhoeal agent may be contained either in the described pharmaceutical composition or in a pharmaceutical formulation independent thereof.
  • Suitable antiemetics include, for example, 5-HT3 receptor antagonists, substituted benzamides, corticosteroids, antihistamines, phenothiazine-type neuroleptics, butyrophenone-type neuroleptics, benzodiazepines, and cannabinoids.
  • Preferred antiemetics include metoclopramide, domperidone and alizapride.
  • Suitable antidiarrhoeal agents include, but are not limited to, the opioids, e.g. Loperamide.
  • the solid oral pharmaceutical compositions are preferably useful for the preventative treatment of leishmaniasis.
  • Other diseases caused by protozoa include malaria, trypanosomiasis, toxoplasmosis, babesiosis, amoebic dysentery and lambliasis.
  • Example 1 hard gelatin capsule (content: 10 mg of miltefosine)
  • hexadecylphosphocholine 100 g of hexadecylphosphocholine, 808.50 g of lactose, 448.50 g of microcrystalline cellulose, 26 g of talc and 13 g of finely divided silica are passed through a sieve with a mesh size of 0.8 mm and then homogenized for 30 minutes in a suitable mixer. Then add 4 g of magnesium stearate (0.8 mm sieve) and mix the components for another 5 minutes. The resulting mixture is filled in known manner in 140 mg portions into hard gelatin capsules weighing 50 mg, using a suitable encapsulating machine. Each of the capsules thus obtained (total weight: 190 mg) contains 10 mg of hexadecylphosphocholine. The ratio of hexadecylphosphocholine: flow agent / surfactant: fillers in the filling mixture is 1: 0.4: 12.4 (parts by weight).
  • Example 2 hard gelatin capsule (content: 100 mg of miltefosine)
  • the resulting filling mixture is filled in known manner into 200 mg portions in hard gelatin capsules weighing 76 mg, using a suitable encapsulating machine.
  • Each of the capsules thus obtained contains 100 mg of hexadecylphosphocholine.
  • the ratio of hexadecylphosphocholine: flow agent: fillers in the filling mixture is 1: 0.07: 0.9 (parts by weight).
  • Example 3 Hard gelatin capsule (content: 250 mg of Miltefosine)
  • Example 2 250 g of hexadecylphosphocholine, 80 g of lactose, 50 g of microcrystalline cellulose, 5 g of talc, 5 g of finely divided silicon dioxide and 15 g of magnesium stearate were mixed according to Example 1.
  • the thus obtained Filling mixture is filled in known manner in 405 mg portions in hard gelatin capsules with a weight of 97 mg, using a suitable Einkapselmaschine.
  • Each of the capsules thus obtained has a total weight of 502 mg and contains 250 mg of hexadecylphosphocholine.
  • the ratio of hexadecylphosphocholine: flow agent: fillers in the filling mixture is 1: 0.1: 0.52 (parts by weight).
  • Example 4 Tablets (content: 250 mg hexadecylphosphocholine)
  • hexadecylphosphocholine 50 g of hexadecylphosphocholine, 24.25 g of microcrystalline cellulose and 22.00 g of anhydrous dicalcium phosphate are sieved and blended. 3.75 g of magnesium stearate are sieved and added to the mixture. The mixture is then mixed again. The resulting mixture is then compressed into tablets weighing 500 mg each. The tablets each contain 250 mg of hexadecylphosphocholine. The ratio of hexadecylphosphocholine: flow agent / surfactant: fillers in the tablet is 1: 0.07: 0.925 (parts by weight).
  • Example 5 Tablets (content: 30 mg hexadecylphosphocholine)
  • the resulting mixture is then compressed into tablets weighing 130.5 mg each.
  • the tablets each contain 30 mg of hexadecylphosphocholine.
  • Fillers in the tablet is 1: 0.087: 0.31 (parts by weight).
  • Example 6 Effervescent Tablets and Effervescent Mixture (content of hexadecylphosphocholine: 250 mg) 1700 g of granular sodium bicarbonate are heated in an oven at 100 ° C for 60 min. After cooling to room temperature, the converted bicarbonate is mixed with 160 g of granular monobasic calcium phosphate, 1030 g of granular anhydrous citric acid, 100 g of talc and 50 g of magnesium stearate. The 'mixture thus obtained is mixed with 300 g of hexadecylphosphocholine und blended for 10 minutes.
  • the effervescent mixture thus obtained is compressed into tablets each weighing 278 mg.
  • the effervescent tablets each contain 250 mg of hexadecylphosphocholine.
  • the ratio of hexadecylphosphocholine: flow agent / surfactant: fillers in the tablet is 1: 0.50: 0.53 (parts by weight).
  • Example 7 Effervescent Tablets and Effervescent Mix (Content: 50 mg hexadecylphosphocholine)
  • 1600 g of granular sodium bicarbonate are heated in an oven at 100 ° C for 60 minutes. After cooling to room temperature, the converted bicarbonate is mixed with 150 g of granular monobasic calcium phosphate, 900 g of granular anhydrous citric acid, 80 g of talc and 30 g of magnesium stearate. The mixture thus obtained is admixed with 200 g of hexadecylphosphocholine and mixed for 10 minutes.
  • the resulting mixture is compressed into tablets weighing 740 mg each.
  • the effervescent tablets each contain 50 mg of hexadecylphosphocholine.
  • the ratio of hexadecylphosphocholine: flow agent / surfactant: fillers in the tablet is 1: 0.55: 0.75 (parts by weight).
  • Example 8 Drinking mixture (sachets) (content: 50 mg hexadecylphosphocholine)
  • hexadecylphosphocholine 5 g of hexadecylphosphocholine, 308 g of lactose, 280 g of microcrystalline cellulose, 5 g of saccharin and 2 g of colloidal silica are mixed.
  • the mixture is filled into sachets.
  • the sachets each weigh 6 g and contain 50 mg of hexadecylphosphocholine.
  • the ratio of hexadecylphosphocholine: flow agent surfactant: fillers in the mixture is 1: 0.4: 117.5 (parts by weight).
  • Example 9 Drinking mixture (sachets) (content: 200 mg hexadecylphosphocholine)
  • the examples may also contain perifosine instead of the active ingredient miltefosine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03731619A 2002-01-25 2003-01-07 Verwendung von alkylphosphocholinen in der pr ventivbehandlung von protozoenerkrankungen Ceased EP1467742A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10203195A DE10203195A1 (de) 2002-01-25 2002-01-25 Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
DE10203195 2002-01-25
PCT/EP2003/000072 WO2003061669A1 (de) 2002-01-25 2003-01-07 Verwendung von alkylphosphocholinen in der präventivbehandlung von protozoenerkrankungen

Publications (1)

Publication Number Publication Date
EP1467742A1 true EP1467742A1 (de) 2004-10-20

Family

ID=7713213

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03731619A Ceased EP1467742A1 (de) 2002-01-25 2003-01-07 Verwendung von alkylphosphocholinen in der pr ventivbehandlung von protozoenerkrankungen

Country Status (16)

Country Link
EP (1) EP1467742A1 (https=)
JP (1) JP2005515244A (https=)
CN (1) CN1622811A (https=)
AR (1) AR038224A1 (https=)
AU (1) AU2003236787B2 (https=)
BR (1) BR0307021A (https=)
CA (1) CA2470185A1 (https=)
CO (1) CO5601024A2 (https=)
DE (1) DE10203195A1 (https=)
IL (2) IL162492A0 (https=)
MX (1) MXPA04007193A (https=)
NZ (1) NZ548040A (https=)
PE (1) PE20030732A1 (https=)
TW (1) TWI339582B (https=)
WO (1) WO2003061669A1 (https=)
ZA (1) ZA200404690B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT501545B1 (de) * 2005-02-23 2007-10-15 Obwaller Andreas Dr Reinigungsmittel für kontaktlinsen
CA2632449A1 (en) * 2005-12-19 2007-06-28 Aeterna Zentaris Gmbh Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4132345A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Ether-lysolecithine und alkylphosphocholine in liposomen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
BR9306040A (pt) * 1992-03-06 1997-11-18 Statens Seruminstitut Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
ES2175663T3 (es) * 1998-01-22 2002-11-16 Zentaris Ag Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
DE10020812C2 (de) * 2000-04-20 2003-06-26 Robert Koch Inst Verwendung von Naphthindazol-4,9-chinonen als Antiparasitika
AU2002232400A1 (en) * 2000-11-06 2002-05-15 U.S. Army Medical Research And Materiel Command Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03061669A1 *

Also Published As

Publication number Publication date
MXPA04007193A (es) 2004-10-29
NZ548040A (en) 2007-06-29
TW200302103A (en) 2003-08-01
BR0307021A (pt) 2004-11-03
AR038224A1 (es) 2005-01-05
JP2005515244A (ja) 2005-05-26
IL162492A0 (en) 2005-11-20
TWI339582B (en) 2011-04-01
IL162492A (en) 2009-12-24
ZA200404690B (en) 2004-09-27
CA2470185A1 (en) 2003-07-31
AU2003236787B2 (en) 2007-03-22
PE20030732A1 (es) 2003-09-27
CN1622811A (zh) 2005-06-01
WO2003061669A1 (de) 2003-07-31
DE10203195A1 (de) 2003-08-07
CO5601024A2 (es) 2006-01-31

Similar Documents

Publication Publication Date Title
DE3586545T2 (de) Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
DE68928920T2 (de) Fettsäure-arzneimittel-konjugat zur verabreichung von arzneimitteln durch die blut-gehirn-schranke
EP0241809A1 (de) Synergistische Kombination von Amantadin und Selegilin
EP0534445B1 (de) Verfahren zur Herstellung eines Arzneimittels zur oralen oder topischen Verabreichung bei der Behandlung von Leishmaniasis
DE2224534B2 (de) Pharmazeutisches praeparat mit langsamer wirkstoffabgabe
DE69804865T2 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
DE3786893T2 (de) Piperidinderivat zur Schmerzbehandlung.
EP0625355B2 (de) Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff
LU84892A1 (fr) Komposition zur reduktion der sebumsekretion
DE69721756T2 (de) Paroxetine zur behandlung von depression
EP1467742A1 (de) Verwendung von alkylphosphocholinen in der pr ventivbehandlung von protozoenerkrankungen
US7887817B2 (en) Process for preventing protozoal diseases
DE4401554A1 (de) Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
DE69725613T2 (de) Neue therapeutische verwendung eines thienylcyclohexylaminderivates
DE602004011486T2 (de) Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas
EP0417637A2 (de) Verwendung von Dopamin-Autorezeptor-Agonisten bei der Behandlung von Drogenabhängigkeit
EP0177853B1 (de) Antirheumatisch wirksame Suppositorien und Verfahren zu deren Herstellung
DE2605243A1 (de) Pyrazolessigsaeurehaltiges arzneimittel
DE2629200A1 (de) Oral verabfolgbares festes antidepressionsmittel und dessen herstellung
DE60121142T2 (de) Zusammensetzung die paracetamol und niflumic säure enthält
DE3820817C2 (de) Antileptikum
DE2537122A1 (de) Pharmazeutische formulierungen und verfahren zur behandlung oder prophylaxe von malaria
DE2512893A1 (de) Zusammensetzung zum zeitweiligen abschwaechen von depressionssymptomen
DE1967186C3 (de) Arzneimittel, enthaltend 4,4-Diarylpiperidine
EP0324348A2 (de) Piperidincarboxamid-Derivate zur Behandlung von Bradycardien und Bradyarrhythmien

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040608

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ZENTARIS GMBH

17Q First examination report despatched

Effective date: 20061027

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AETERNA ZENTARIS GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100302